Relatório global de análise do tamanho, quota e tendências do mercado de tratamento da narcolepsia – Visão geral do setor e previsão para 2031

Análise de mercado do tratamento da narcolepsia

O mercado do tratamento da narcolepsia está a assistir a um crescimento substancial devido à crescente prevalência da narcolepsia e aos avanços nas opções de tratamento. Os tratamentos emergentes, como os antagonistas dos recetores da orexina, estão a melhorar as abordagens terapêuticas, visando as vias subjacentes na fisiopatologia da narcolepsia. Recentemente, empresas como a Avadel e a Jazz Pharmaceuticals têm ganho atenção com medicamentos inovadores que apresentam resultados promissores no tratamento mais eficaz dos sintomas da narcolepsia. A expansão do mercado é também apoiada por uma maior consciencialização sobre os distúrbios do sono e por melhores taxas de diagnóstico. Prevê-se que o crescimento continue à medida que a I&D em neuroterapêutica e os avanços na telemedicina melhoram o diagnóstico e o acesso aos cuidados, beneficiando os doentes e apoiando a dinâmica do mercado.

Tamanho do mercado de tratamento da narcolepsia

O tamanho global do mercado de tratamento da narcolepsia foi avaliado em 3,15 mil milhões de dólares em 2023 e deverá atingir os 7,00 mil milhões de dólares até 2031, com um CAGR de 10,50% durante o período de previsão de 2024 a 2031. Para além dos insights sobre os cenários de mercado, como o valor de mercado, a taxa de crescimento, a segmentação, a cobertura geográfica e os grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também a análise especializada aprofundada, a epidemiologia dos pacientes, a análise de pipeline, a análise de preços e a estrutura regulatória.

Tendências do mercado de tratamento da narcolepsia

“ Avanços nos tratamentos farmacológicos”

O mercado de tratamento da narcolepsia está a evoluir com um forte foco na inovação para melhorar os cuidados prestados aos doentes e satisfazer as necessidades não satisfeitas na gestão da sonolência diurna excessiva e da cataplexia. Os avanços nos tratamentos farmacológicos estão a impulsionar o crescimento, com novas classes de medicamentos, incluindo antagonistas dos recetores de orexina, a mostrarem potencial no combate eficaz às causas profundas da narcolepsia. Uma tendência notável no mercado é o desenvolvimento de medicamentos de ação prolongada que reduzem a frequência das doses, melhorando a adesão dos doentes e a qualidade de vida. As inovações na telemedicina e nas tecnologias de saúde wearable estão também a ajudar a monitorizar os distúrbios do sono de forma mais eficiente, tornando o tratamento mais acessível. Com a crescente consciencialização e melhores taxas de diagnóstico, o mercado está preparado para oferecer uma gama mais ampla de opções de tratamento eficazes e personalizadas para a narcolepsia.

Âmbito do relatório e segmentação do mercado de tratamento da narcolepsia       

Definição de mercado de tratamento da narcolepsia

O tratamento da narcolepsia abrange estratégias e intervenções médicas destinadas a controlar os sintomas da narcolepsia, uma condição neurológica crónica marcada por sonolência diurna excessiva, episódios súbitos de sono e, por vezes, cataplexia (uma perda súbita de tónus muscular desencadeada pela emoção) .

Dinâmica do mercado de tratamento da narcolepsia

Motoristas

• Aumento da incidência de narcolepsia

The rising incidence of narcolepsy is a significant driver of the treatment market. As awareness of this condition increases among both healthcare professionals and the general public, more individuals are being diagnosed and seeking effective management options. This heightened awareness facilitates earlier diagnosis and encourages individuals to pursue treatment, leading to an increased demand for targeted therapies. Consequently, pharmaceutical companies are motivated to develop innovative treatment solutions to address the growing patient population, ultimately driving market growth.

• Advancements in Selective Histamine H3-Receptor Antagonists

The development in the field of narcolepsy treatment have resulted in the emergence of new and innovative therapies that significantly enhance patient care. The introduction of selective histamine H3-receptor antagonists and novel stimulant medications exemplifies this progress, offering improved symptom management for individuals affected by narcolepsy. These advancements provide more effective treatment options and cater to diverse patient needs, enabling tailored approaches to symptom control. As healthcare providers gain access to these cutting-edge treatments, the overall demand for narcolepsy therapies is expected to rise, driving market growth and improving the quality of life for patients.

Opportunities

• Integration of New Drug Classes

The emergence of new drug classes, particularly orexin receptor antagonists and gene therapies, presents significant opportunities in the narcolepsy treatment market. Orexin receptor antagonists target the underlying mechanisms of narcolepsy, providing a novel approach to managing symptoms and improving sleep quality. Additionally, gene therapies aim to address the genetic factors contributing to the disorder, offering the potential for long-term solutions. These advancements can fill existing gaps in treatment options, enhance patient outcomes, and attract attention from pharmaceutical companies seeking to innovate in a market that is increasingly focused on personalized medicine and effective symptom management.

• Rising Integration of Wearable Devices

The integration of wearable devices and mobile applications into the narcolepsy treatment landscape offers substantial market opportunities by enhancing patient engagement and improving treatment outcomes. These technologies allow for real-time monitoring of symptoms, enabling patients to track their sleep patterns, alertness levels, and medication adherence. With data readily available, healthcare providers can make informed decisions and tailor treatment plans to individual needs. Additionally, increased patient engagement through these platforms fosters a proactive approach to managing narcolepsy, ultimately leading to better adherence to prescribed therapies and improved quality of life. This trend reflects the growing emphasis on digital health solutions in modern healthcare.

Restraints/Challenges

• Limited Treatment Options

Despite the availability of various treatments for narcolepsy, options can remain limited, especially for patients experiencing specific symptoms or those with comorbid conditions. For instance, individuals who also suffer from psychiatric disorders or sleep apnea may not respond effectively to standard treatments, highlighting the need for tailored therapeutic approaches. This limitation necessitates ongoing research and development of diverse therapies that can cater to a broader range of symptoms and patient profiles. The lack of comprehensive treatment options can hinder effective symptom management and overall patient satisfaction, ultimately posing a challenge for healthcare providers and the narcolepsy treatment market.

•  High Cost of Narcolepsy Medications

The high cost of many narcolepsy treatment medications presents a significant barrier to patient access and adherence to treatment regimens. For individuals without sufficient insurance coverage, the financial burden can be overwhelming, leading to delays in seeking necessary medical care. This situation may force patients to make difficult choices between essential medications and other living expenses. Consequently, limited access to effective treatments can adversely affect overall patient outcomes, leading to increased morbidity associated with narcolepsy symptoms. As a result, the financial implications of narcolepsy treatments serve as a critical restraint on market growth, emphasizing the need for more affordable therapeutic options.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Narcolepsy Treatment Market Scope

The market is segmented on the basis of type, drugs, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Type 1 Narcolepsy
• Type 2 Narcolepsy

Drugs

• Selective Histamine H3-Receptor Antagonist
• Stimulants
• Serotonin Reuptake Inhibitors
• Tricyclic Antidepressants
• Central Nervous System Depressant
• Others

Route of Administration

• Oral
• Injectable

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

 Narcolepsy Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, drugs, route of administration, end-users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the narcolepsy treatment market, driven by escalating healthcare expenditures and a robust focus on research and development. The region's commitment to innovation and the adoption of advanced technologies further enhance its market position. These factors collectively contribute to the region's dominance in providing effective narcolepsy treatments.

Asia-Pacific region is projected to experience the highest growth rate from 2024 to 2031, fueled by strategic initiatives implemented by key market players. Additionally, supportive government policies aimed at enhancing healthcare access and innovation play a crucial role in this growth. Together, these factors are expected to significantly drive the narcolepsy treatment market in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Narcolepsy Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Narcolepsy Treatment Market Leaders Operating in the Market Are:

• Avadel (Ireland)
• Vallon Pharmaceuticals (U.S.)
• Jazz Pharmaceuticals, Inc. (Ireland)
• Jubilant Pharmova Limited (India)
• BIOPROJET (France)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC (EUA)
• Teva Pharmaceutical Industries Ltd (Irlanda)
• Ligand Pharmaceuticals Incorporated (EUA)
• Novartis AG (Suíça)
• (EUA)
• Alkem (Índia)
• Alembic Pharmaceuticals Limited (Índia)
• Torrent Pharmaceuticals Ltd (Índia)
• Johnson & Johnson Private Limited (EUA)
• F. Hoffmann-La Roche Ltd. (Suíça)
• Grupo Zydus (Índia)

Últimos desenvolvimentos no mercado de tratamento da narcolepsia

• Em março de 2022, a Jazz Pharmaceuticals anunciou um acordo definitivo para adquirir o Sunosi (solriamfetol), um medicamento utilizado para tratar a sonolência diurna excessiva em doentes adultos com narcolepsia ou apneia obstrutiva do sono (AOS). A aquisição deverá estar concluída no segundo trimestre de 2022. Este movimento estratégico visa melhorar o portefólio de tratamentos para distúrbios do sono da Jazz
• Em fevereiro de 2022, a Takeda Pharmaceutical Company Limited anunciou o envio de um Pedido de Novo Medicamento (NDA) para o TAK-998, também conhecido como Wakixol, à Food and Drug Administration (FDA) dos EUA. Este medicamento oral inovador funciona como um inibidor da recaptação de dopamina e noradrenalina (DNRI) e foi desenvolvido especificamente para tratar a cataplexia em doentes adultos com diagnóstico de narcolepsia. O pedido representa um avanço significativo no compromisso da Takeda em satisfazer as necessidades das pessoas afetadas pela narcolepsia
• Em janeiro de 2022, a Harmony Biosciences LLC anunciou o início de um ensaio clínico de Fase 3 para o pitolisant, um antagonista do recetor H3 da histamina. Este ensaio tem como objetivo avaliar a eficácia do pitolisant no tratamento de adultos com narcolepsia com sonolência diurna excessiva (SDE). O estudo representa um avanço significativo no desenvolvimento de terapias dirigidas a indivíduos que sofrem deste sintoma debilitante da narcolepsia.
• Em janeiro de 2020, a Axsome Therapeutics, Inc., uma empresa biofarmacêutica focada no desenvolvimento de terapias inovadoras para distúrbios do sistema nervoso central, obteve uma licença exclusiva nos EUA da Pfizer Inc. Este acordo concede à Axsome acesso aos dados clínicos e não clínicos da Pfizer, bem como aos dados intelectuais propriedade relacionada com a reboxetina, princípio farmacêutico ativo do AXS-12, que está a ser desenvolvido para o tratamento da narcolepsia. Espera-se que esta colaboração melhore as capacidades da Axsome no avanço do desenvolvimento do AXS-12   

SKU-47800